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The authors compare in their database including all patients with lung 
cancer since January 1990, the 160 patients included in 1990-5 (cohort 
A), and the 507 patients included in 2000-5 (cohort B).
The comparison shows, signiﬁcatively, an increase of number of lung 
cancer, an increase of women (A: 12 %, B: 25 %), of adenocarcinomas 
(A: 30 %, B: 53 %), of stage IV (A: 33 %, B: 44 %) and a reduction of 
squamous cell carcinomas (A: 41 %, B: 23 %), of stage IIIB ( A: 22 %, 
B: 12 %). Small cell lung cancer is stable (A: 11 %, B: 9 %).
Tobacco use is more important in cohort A (97%) than in B(92%). Age 
of both cohorts is the same (63.4 and 63.8 years)
In both cohorts, diagnosis is suspected in 77 % in front of symptoms.
The diagnosis is done in cohort A by endoscopy (70 %) and in cohort B 
by endoscopy (43%) and by CT-Transthoracic punction (20%).
Global survival is better in cohort B, 14.7 months, than in cohort A, 
10.7 months (p<0.002).
All TNM stages have a best survival in cohort B, but it is only sig-
niﬁcant for stage IV, PS 0-1 patients (B: 10.5 months, A: 6.7 months, 
p<0.0003) and for stage IIIB patients (B: 13.2 months, A: 9.3 months, 
p<0.0004). 
For the histology, for the gender, the difference are not signiﬁcant.
This best result seems due to a best selection of patients (Pet scan, RMI 
staging), to an increase of number of chemotherapy treatment in stage 
IV, in ﬁrst and second line, and to an use of third generation drugs. 
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(ECOG) studies using age of 60 years or older as a surrogate 
marker
Wakelee, Heather A.1 Dahlberg, Suzanne E.2 Schiller, Joan H.3 Langer, 
Corey J.4 Sandler, Alan B.5 Brahmer, Julie R.6 Belani, Chandra P.7 
Johnson, David H.5 
1 Stanford University, Stanford, CA, USA 2 Dana Farber Cancer In-
stitute/ECOG, Boston, MA, USA 3 University of Texas - Southwestern, 
Dallas, TX, USA 4 Fox Chase Cancer Institute, Philadelphia, PA, USA 5 
Vanderbilt University, Nashville, TN, USA 6 Johns Hopkins University, 
Baltimore, MD, USA 7 University of Pittsburgh, Pittsburgh, PA, USA 
Background: Women with advanced NSCLC tend to live longer than 
men for unclear reasons. A recent Southwest Oncology Group (SWOG) 
analysis of six trials of patients with advanced stage NSCLC (N=1334) 
again showed a survival advantage for women versus men, but interest-
ingly noted a cut-point for women around age 60, such that older wom-
en tended to live longer than younger women.(Albain IASLC-Chicago 
2006) Menopausal status was postulated as one explanation given the 
role of estrogen in lung cancer. To further explore this observation, we 
evaluated pooled data from two large ECOG trials, E1594 and E4599. 
Methods: E1594 randomized patients with advanced NSCLC to one of 
four platinum containing two-drug combination regimens, all of which 
had comparable efﬁcacy. E4599 randomized patients to carboplatin/pa-
clitaxel (one of the regimens on E1594) with or without bevacizumab. 
Because of confounding factors with bevacizumab, only the control 
arm is included in this analysis. Eligible patients from both E1594 
and the control arm of E4599 (N=1590) were divided into male and 
female cohorts and separated into age groups of < 60 or ≥ 60 years old. 
Survival was calculated separately for each cohort using the method of 
Kaplan-Meier. Known prognostic factors such as performance status, 
weight loss, and stage were also compared for each gender/age cohort 
using two-sided Fisher’s exact tests.
Results: 1590 eligible patients were included in this analysis consisting 
of 611 (38%) women and 979 (62%) men. 274 (45%) and 390 (40%) of 
women and men respectively were < 60 years old. A higher propor-
tion of those ≥ 60 were male (p=0.05), but there was no other statisti-
cally signiﬁcant differences in known prognostic factors between the 
4 gender/age cohorts. A statistically signiﬁcant difference in survival, 
however, was found. The median survival time (MST) for women ≥ 60 
years old was 11.6 months, versus 9.0 months for women < 60 (logrank 
p=.03). Men overall had lower survival than women, but no difference 
was seen for older men (MST of 7.4 months) versus men < 60 years 
old (MST of 8.3 months). Progression free survival (PFS) was also 
better for older women (4.7 months for those ≥ 60 years old versus 3.8 
months for younger women (logrank p =.009). Again no difference was 
seen for PFS for men of different ages, but men overall had shorter PFS 
than women.
Conclusions: As shown previously, women with advanced stage 
NSCLC live longer than men with the disease but the survival ad-
vantage is primarily for post-menopausal women at least 60 years of 
age. Known prognostic factors such as performance status, signiﬁcant 
weight loss, and stage cannot account for this difference. Men did 
not show a difference in survival by age. These data may indicate 
an important difference in lung cancer survival modiﬁed by meno-
pausal status. These data and the recent SWOG analysis make further 
investigation into the role of the estrogen pathway in lung cancer more 
compelling.
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Background: Histone methyltransferase (HMT) enzymes that methyl-
ate lysine residues of histone are involved in chromatin-mediated gene 
expression. The human homolog of the Drosophila gene Enhancer 
of Zeste 2 (EZH2) contains a highly conserved motif called the SET 
domain that required for the HMT activity. EZH2 has an important role 
in methylating histone H3 on Lys27, which leads to gene scilencing. 
Overexpression of the transcriptional repressor EZH2 was reported to 
be associated with the poor prognosis in various malignancies includ-
ing breast cancer and prostate cancer. In this study, we investigated the 
association between EZH2 polymorphisms and lung cancer risk. 
Materials and Methods: In a hospital-based study of 335 lung cancer 
patients and 335 age-, gender-matched healthy controls, 37 polymor-
phisms of EZH2 were examined. Of the 335 lung cancer patients, 189 
(56%) had adenocarcinomas, 77 (30%) had squamous cell carcinomas 
and 29 (9%) had small cell lung cancer. For a highly multiplexed SNP 
genotyping, the GoldenGate genotyping assay (Illumina Inc.) that 
combines an oligonucleotide ligation and allele-speciﬁc extension reac-
tion was performed. Statistical analyses were performed using logistic 
regression models with the adjustment for smoking status, pack-years 
and family history of cancer.
Results: All genotyped polymorphisms of EZH2 were in Hardy-Wein-
berg equilibrium in normal control population. When all age groups 
were analyzed together, one variant genotype of +19639A>G showed a 
signiﬁcant association with the reduced risk of lung cancer (AOR=0.72, 
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95% CI: 0.56-0.94). Stronger association between EZH2 polymor-
phisms and the reduced lung cancer risk was observed particularly in 
younger age group (< 58 years). Associated polymorphisms were -
12712T>A, -4003C>G, and -529G>A in intron 1, +35558C>T in intron 
15, and +38931G>C in intron 19 (AOR = 0.65~0.68, P = 0.02~0.04). 
One haplotype (ht2) of EZH2 was signiﬁcantly associated with the 
reduced lung cancer risk in overall group (AOR = 0.72, 95% CI: 0.55-
0.93) as well as in younger age group (AOR=0.66, 95% CI: 0.45-0.96). 
Conclusion: This is the ﬁrst study to show a signiﬁcant associa-
tion between polymorphisms of the EZH2 gene and the lung cancer 
risk, particularly in younger age group. This study suggested that the 
presence of variant allele in EZH2 may be a protective factor for lung 
cancer, hence an important marker for lung cancer susceptibility.
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Mortality due to malignant diseases  increased  for about  28%   from 
1990-2002. in Serbia. Every third patient has the advanced disease at 
the time of diagnosis. 
The aim of the survey was to estimate some aspects of health system  
concerning malignant diseases, preferably lung cancer, in Serbia. The 
survey (“face to face”) on public opinion  comprised 1023 persons 
- represantative sample, 171 cancer patients (pts) - majority with lung 
cancer,  and  162 doctors- majority dealing mostly  with lung cancer: 
their  attitudes about  national health funding for malignant diseases, 
cancer patients position and problems during the disease course, pro-
vided disease-related informations to pts, and diagnostic access i.e. de-
lays. All 3 groups think that not enough money  is  provided for health 
and it is not well distributed. Doctors and pts agree that cancer pts 
position is pretty bad,  worse  than others; the most  frequent patients 
problems for both  the same: not well informed about  the disease, late 
diagnosis and  drug availability. The time from the onset of symptoms  
until referring to the doctor  was in average 182 days, and to establish 
the diagnosis additional 78 days.
Doctors ﬁnd the crucial problems to be:  going to see the doctor too 
late,  in many cases lack of adequate facilities and too many  pts who 
need it.
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Background: With the advent of high resolution CT, the incidence of 
small lung lesions continues to increase. It is very difﬁcult to diagnose 
these lesions with conventional bronchoscopy, and partial resection just 
for diagnosis should be minimized for the patient as well as medical 
cost. While signiﬁcant improvements are being made in diagnostic 
bronchoscopy such as virtual bronchoscopy, these devices still require 
further studies. In the present study we analyzed our single institution 
experience of CT guided needle biopsy for small lung nodules. 
Methods: Retrospective analysis was done in 174 cases with lung 
lesions smaller than 2cm. Bronchoscopic diagnosis was attempted at 
least once in all cases. A semi-automatic 18G needle was used with a 
specially designed holding device, and a lead plate which effectively 
minimized radiation exposure of the physician. The patients breathed 
spontaneously throughout the procedure.
Results: 97 were males and 77 were females. Age ranged from 20 to 
91, average 63. The lesions were considered to be so called GGOs 
in 32, and nodules in 142. The lesions were diagnosed as malignant 
in 117, and non-malignant in 57. Overall accuracy was 87.4%. The 
distance from the point of skin penetration to the lesion ranged from 16 
to 112 mm, average 61mm. Pneumothorax was detected in 33 cases. 
Non had symptoms. 31 cases regressed spontaneously. We performed 
prophylactic manual aspiration in 2 cases. Hemosputum was seen in 14 
cases all of which abated spontaneously. 
Comments: At present, we consider percutaneous ﬂuoroscopic CT 
guided needle biopsy can be effective in providing diagnosis for these 
small lung lesions. Concerns still remain regarding the complication of 
air embolism, the mechanism of which is still unclear.
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Purpose: Usefulness of ﬂuorodeoxyglucose (FDG) positron emission 
competed tomography (PET) in diagnosis of lung cancer has been 
reported. We assess the role of FDG PET/CT scan in lymph node stag-
ing of non-small cell lung cancer (NSCLC) and evaluate the maximum 
standard uptake value (SUVmax) of the primary tumor as a predictor of 
lymph node metastasis.
Patients and Method: From March 2006 to December 2006, 81 
preoperative patients with suspected or proven NSCLC were examined 
by FDG-PET/CT. We diagnosed lymph node staging and calculated 
